Biodesix (BDSX) Cash & Equivalents (2019 - 2026)

Biodesix (BDSX) has reported Cash & Equivalents for 8 consecutive years, with $25.6 million the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $25.6 million, up 45.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.6 million (up 45.27% YoY), and the FY2025 annual result was $19.0 million, down 27.65% from the prior year.
• Cash & Equivalents was $25.6 million for Q1 2026 at Biodesix, up from $19.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $43.1 million in Q4 2022 and troughed at $11.5 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $23.4 million, with a median of $20.7 million recorded in 2025.
• Year-over-year, Cash & Equivalents sank 70.36% in 2022 and surged 142.51% in 2024.
• Over 5 years, Cash & Equivalents stood at $43.1 million in 2022, then plunged by 39.0% to $26.3 million in 2023, then fell by 0.15% to $26.2 million in 2024, then decreased by 27.65% to $19.0 million in 2025, then jumped by 34.68% to $25.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $25.6 million in Q1 2026, $19.0 million in Q4 2025, and $16.6 million in Q3 2025.